Trial Summary
What is the purpose of this trial?The purpose of this clinical trial is to learn if the drugs Pirtobrutinib and Rituximab are effective for the treatment of newly diagnosed marginal zone lymphoma.
Eligibility Criteria
This trial is for patients newly diagnosed with marginal zone lymphoma, a type of cancer affecting white blood cells. Participants should be suitable for both biopsy and imaging tests like CT and PET scans to monitor the disease.Inclusion Criteria
My lymphoma type is confirmed as marginal zone lymphoma.
I am 18 years old or older.
I can take care of myself and am up and about more than 50% of my waking hours.
Exclusion Criteria
I have a condition that affects how my body absorbs nutrients.
I have not had major surgery in the last 4 weeks.
I have a history of unusual bleeding.
I do not have serious heart problems.
My cancer has spread to my brain or spinal cord.
I am positive for HIV, HBV, or HCV.
I need blood thinners like warfarin for my condition.
I haven't had any live-virus vaccines in the last 28 days and don't need any during the study.
I have an active, uncontrolled immune system disorder affecting my blood cells.
Treatment Details
The study is testing pirtobrutinib combined with rituximab as a treatment. Pirtobrutinib blocks proteins that help tumor cells grow, while rituximab targets certain immune cells potentially aiding in killing cancer cells.
1Treatment groups
Experimental Treatment
Group I: Treatment: All PatientsExperimental Treatment1 Intervention
The study's goal is to investigate the efficacy of the combination of study drugs pirtobrutinib and rituximab.
Pirtobrutinib is already approved in United States for the following indications:
🇺🇸 Approved in United States as Jaypirca for:
- Mantle Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Find a clinic near you
Research locations nearbySelect from list below to view details:
Huntsman Cancer Institute at University of UtahSalt Lake City, UT
Ohio State University Comprehensive Cancer CenterColumbus, OH
Loading ...
Who is running the clinical trial?
Narendranath EpperlaLead Sponsor
University of UtahLead Sponsor
Eli Lilly and CompanyIndustry Sponsor